Chutes & Ladders: Interim CEO resigns from troubled Able Laboratories

Robert G. Mauro, the president and interim CEO of troubled Able Laboratories, has resigned. In a statement, Able announced: "The ongoing disruption in the company's operations caused by its product recall and the suspension of manufacturing activities has had, and will continue to have, a material adverse effect on the company's results of operations and financial position. Able can give no assurance as to if or when it will be able to resume manufacturing operations."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.